RENN Health Tirzepatide Review: One Price, No Billing Cycle (2026)

RENN Health publishes exactly one tirzepatide figure — "Tirzepatide As Low As $199/month" — and it states no billing cycle, no inclusions and no ladder behind it, which is why we give the program no sortable monthly rate. A 22-screen walk of RENN's own intake on 1 September 2026 reached the final attestation screen without one dollar figure appearing, and no month-to-month price is published anywhere on joinrenn.com.¹

The one figure it publishes, and the pages around it

That floor is printed four times on the homepage and once more on the tirzepatide page, never with a term beside it. The memberships page, which sits in RENN's own sitemap and navigation, ships unedited template copy reading "Membership 1 / Short description placeholder. / Placeholder". No refund, cancellation or auto-renewal terms exist anywhere on a site selling three- and six-month prepay bundles; a census of thirteen pages and all 22 intake screens on 1 September found none of those words.

Six pharmacies, two physicians, and the letter behind one name

What RENN does disclose, it discloses properly. A homepage FAQ names six pharmacies — Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills — each with a phone number and a website. A second names the medical group Lion MD, plus Dr. Ana Lisa Carr and Dr. Kelly Tenbrink, both with their NPIs. One of those six carries something attached. Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy, the pharmacy RENN Health names on its own pages, received an FDA warning letter in March 2023; FDA publishes the letter itself, and it does not name RENN Health.² That is an action against a pharmacy, not against RENN Health, which is itself clean on FDA's index. No 503A or 503B designation is given for any of the six.

The brand-vs-compounded question

RENN dispenses compounded tirzepatide, and its marketing site never uses the word compounded. The disclosure lives only in product descriptions inside the intake application's catalog, which patients never see. A compounded drug is pharmacy-made, is not an FDA-approved finished product, and was not what the pivotal trials tested — our guide to whether compounded tirzepatide is still legal in 2026 sets out where that leaves a buyer.

How the care model holds up

The strengths are all names: six pharmacies with contact details, a medical group, two physicians with NPIs, and an intake selector enumerating fifty states plus the District of Columbia and Puerto Rico. The weaknesses are structural: no legal entity, state of formation or street address is published, and the Terms state governing law twice and differently — once as the laws of the United States, once as California with exclusive California venue. RENN prints six pharmacy phone numbers while keeping its own out of the footer.

Does the drug work? (Separate from the provider)

The molecule and the merchant are separate questions, and only the second is in doubt here. Tirzepatide's trial record is about as good as obesity medicine gets: roughly 15% to 21% of starting body weight over 72 weeks in SURMOUNT-1³, and a clear win over semaglutide head to head in SURMOUNT-5⁴. Both ran on the branded product at approved doses, a caveat for any compounded purchase; our tirzepatide evidence guide unpacks it.

The honest verdict

RENN is unusually forthcoming about who touches the prescription and unusually quiet about what it costs. If the disclosure is the draw, weigh it against AHBARx, which names one pharmacy rather than six but prints $349 a month before you commit anything. Or against SexyMD, whose four-week rate is $369 and whose commitment ladder is published with every term labeled, so the headline can be checked against it. RENN offers neither a term nor a ladder, and the truthful answer to what tirzepatide costs here is that the site does not say. Our ranked best tirzepatide providers list has the rest of the field.